NCT05918159

Brief Summary

This is a observational study, that aimed to determine the prevalence of sarcopenia using European Wording Group on Sarcopenia in Older People (EWGSOP) algorithm in a general elderly population in Algarve region (Portugal). Because muscle is metabolically active tissue, sarcopenia may also contribute to the development of some of the metabolic disorders associated with aging. However, the risk factors associated with sarcopenia are poorly understood. Thus, a cross-sectional survey of a sample of 274 elderly adults aged 60 or over, were included in the study. Correlations of sarcopenia with functional level, lipid and glycemic profile, nutritional and physical activity level, fall risk, quality of life, and self-reported comorbidities will be studied.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
274

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 14, 2019

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2023

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 15, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 26, 2023

Completed
Last Updated

August 14, 2023

Status Verified

August 1, 2023

Enrollment Period

3.8 years

First QC Date

June 15, 2023

Last Update Submit

August 9, 2023

Conditions

SarcopeniaSarcopenic ObesityFrailty

Keywords

SarcopeniaQuality of LifeFrailtyMuscle StrengthAgingBody CompositionPostural BalanceFalls

Outcome Measures

Primary Outcomes (2)

  • Prevalence of Sarcopenia in elderly population

    Determine the prevalence of sarcopenia using European Wording Group on Sarcopenia in Older People (EWGSOP) algorithm in a general elderly population in Algarve region.

    0 Months

  • Quality of life in elderly population

    Quality of life was assessed at one time point only (due to the nature of the cross-sectional study design) using the subscore and total score of Medical Outcomes Study 36-item Short-Form Health Survey instrument. Instrument scores can range between 0 - 100. Higher values mean better self-perception of quality of life.

    0 Months

Secondary Outcomes (34)

  • Cognitive Assessment

    0 Months

  • Body mass index (kg/m2) - body composition

    0 Months

  • Fat Mass (kg and %) - body composition

    0 Months

  • Fat-Free Mass (kg and %) - body composition

    0 Months

  • Fat Mass Index (kg/m2) - body composition

    0 Months

  • +29 more secondary outcomes

Study Arms (1)

Elderly

Group of 274 elderly

Other: Sarcopenia Assessment

Interventions

Sarcopenia AssessmentOTHER

The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.

Elderly

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The participants of this study are people from the community of the Algarve region over 60 years old. To proceed with the recruitment of participants, the study was disseminated through promotional materials, such as flyers and posters in senior universities, institutions/associations, municipalities and parish councils, sports complexes, among other community spaces in the Algarve region. A non-probabilistic sampling was used. The sampling process consisted in a first phase of intentional sampling, which allowed recruiting many individuals over 60 years old who met the inclusion and exclusion criteria and in a second phase the sampling process was also carried out using the snowball method.

You may qualify if:

  • Minimum age of 60 years;
  • Live in the community;
  • Independet Gait.

You may not qualify if:

  • Presence of moderate or severe cognitive impairment;
  • Presence of uncontrolled cardiovascular disease and active cancer;
  • Use of a pacemaker;
  • Use of internal prosthesis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marta Botelho

Faro, Algarve, 8005-139, Portugal

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples were collected with the COBAS b 101 system and after analyzing by the system, the samples were immediately destroyed and deposited in waste suitable for biological residues.

MeSH Terms

Conditions

SarcopeniaFrailty

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and SymptomsPathologic Processes

Study Officials

  • Sandra R Pais, PhD

    Universidade do Algarve

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 15, 2023

First Posted

June 26, 2023

Study Start

May 14, 2019

Primary Completion

February 20, 2023

Study Completion

February 20, 2023

Last Updated

August 14, 2023

Record last verified: 2023-08

Locations

PT(1)